User profiles for B. Y. Chang

Bo Young Chang

Bank of Canada
Verified email at bankofcanada.ca
Cited by 932

Electrochemical impedance spectroscopy

BY Chang, SM Park - Annual Review of Analytical Chemistry, 2010 - annualreviews.org
… signal synthesized by mixing ac waves of various frequencies, followed by fast Fourier …
was used as an excitation source, followed by Fourier transform of both excitation and response …

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

…, AJ Johnson, R Izumi, A Hamdy, BY Chang… - The lancet …, 2014 - thelancet.com
… This study was sponsored by Pharmacyclics. Clinical investigators were responsible for
design of the study protocol and analysis plan together with Pharmacyclics. The investigators …

[HTML][HTML] Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

…, AJ Johnson, J Sukbuntherng, BY Chang… - … England Journal of …, 2013 - Mass Medical Soc
… for treatment; adequate renal and hepatic function, defined by a creatinine level of no more
than 1.5 … levels were performed during the screening period by a central reference laboratory. …

[HTML][HTML] Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

…, J McGreivy, F Clow, JJ Buggy, BY Chang… - … England Journal of …, 2013 - Mass Medical Soc
by the biometrics group at Janssen Research and Development and were independently
confirmed and validated by a … Manuscript drafts were prepared by all the authors, with editorial …

[HTML][HTML] Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

…, S Stilgenbauer, JJ Buggy, BY Chang… - … England Journal of …, 2014 - Mass Medical Soc
… Functional analysis showed that the C481S mutation of BTK results in a protein that is
only reversibly inhibited by ibrutinib. The R665W and L845F mutations in PLCγ2 are both …

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

…, JC Barrientos, J McGreivy, M Fardis, BY Chang… - Nature medicine, 2015 - nature.com
… might mitigate the effect of ibrutinib by providing an alternate means by which to activate
NF-… mutations more often than would be expected by chance in ABC tumors 5 , suggesting …

[HTML][HTML] Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

…, RR Furman, S Rodriguez, BY Chang… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
… Best clinical response (CR, PR, SD, PD) was determined by investigators based on criteria
defined by the International Working Group revised response criteria for malignant lymphoma…

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor–and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

…, CR Geest, E Eldering, BY Chang… - Blood, The Journal …, 2012 - ashpublications.org
… and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which
is … Our data indicate that inhibition of BTK by PCI-32765 overcomes BCR- and chemokine-…

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

…, JD Hessler, TM Liu, BY Chang… - Blood, The Journal …, 2013 - ashpublications.org
… cells and T lymphocytes forms an indispensable component of adaptive immunity, yet certain
neoplastic, autoimmune, parasitic, and infectious diseases subvert adaptive immunity by

Market skewness risk and the cross section of stock returns

BY Chang, P Christoffersen, K Jacobs - Journal of Financial Economics, 2013 - Elsevier
… In this study, we instead estimate the higher moments of market returns by extracting
moments implied by daily index option prices. We use the model-free methodology proposed …